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H I G H L I G H T S
• Ultrasound-based therapies are opening new horizons in the oncological field.
• Innovative and promising solutions derive from different nanoparticles-assisted ultrasound treatments.
• Sonodynamic therapy (SDT) emerged recently as a novel approach for cancer treatment.
• Different and complex cell death mechanisms are involved in nanoparticles-assisted SDT.
• Nanoparticles-assisted ultrasound is still at its infancy in clinics.
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A B S T R A C T
At present, ultrasound radiation is broadly employed in medicine for both diagnostic and therapeutic purposes at
various frequencies and intensities. In this review article, we focus on therapeutically-active nanoparticles (NPs)
when stimulated by ultrasound. We first introduce the different ultrasound-based therapies with special atten-
tion to the techniques involved in the oncological field, then we summarize the different NPs used, ranging from
soft materials, like liposomes or micro/nano-bubbles, to metal and metal oxide NPs. We therefore focus on the
sonodynamic therapy and on the possible working mechanisms under debate of NPs-assisted sonodynamic
treatments. We support the idea that various, complex and synergistics physical–chemical processes take place
during acoustic cavitation and NP activation. Different mechanisms are therefore responsible for the final cancer
cell death and strongly depends not only on the type and structure of NPs or nanocarriers, but also on the way
they interact with the ultrasonic pressure waves. We conclude with a brief overview of the clinical applications
of the various ultrasound therapies and the related use of NPs-assisted ultrasound in clinics, showing that this
very innovative and promising approach is however still at its infancy in the clinical cancer treatment.
1. Introduction
Ultrasound is defined as a type of mechanical sound wave with a
periodic vibration at frequencies higher than the human hearing
(20 kHz). It is generated by exciting at a proper frequency an ultrasonic
transducer (usually based on a piezoelectric component or on an elec-
tromagnetic inductor) able to convert the electrical signal into a me-
chanical displacement [1,2]. Ultrasound devices are usually composed
by a generator, a compensating amplifier and a transducer [3,4].
It is already known that ultrasonic waves cause thermal and non-
thermal effects. In particular, thermal effects refer to an increase in
temperature due to the absorption of the ultrasonic waves through a
tissue creating mechanical compression and decompression. Part of this
mechanical energy is lost due to friction effects and it is converted to
heat. As a consequence, in biological systems [5] the liquidity of the
phospholipid bilayer, composing the cell membranes, changes and the
membrane permeability can alter [6].
The non-thermal effect of ultrasound is a complex and various set of
mechanisms, comprising stable and inertial cavitation, microstreaming
and radiation forces [7]. These events are able to induce both tem-
perature increase and mechanical stresses, those in particular known as
microjets and microstreams [8]. More in details, during non-inertial
cavitation (also called stable cavitation) the gas pockets present in the
liquid oscillate around an equilibrium radius and can persist for many
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acoustic compression and decompression cycles. These oscillations
generate fluid streaming and the mechanical stresses create mixing of
the medium [9]. On the other hand, the inertial cavitation is the process
by which the gas bubbles trapped in a fluid are subjected by a rapid
growth and violent collapse during exposure to ultrasound. During such
collapse, high temperatures (higher than 5000 K) and pressures (more
than 800 atm) are produced, releasing a high amount of energy [9]. The
inertial cavitation is able to induce water thermal dissociation and thus
reactive oxygen species (ROS). Furthermore, cavitation generates fla-
shes of light, a phenomenon called sonoluminescence (SL) [9].
Ultrasound is largely employed at present in medicine for diagnostic
and therapeutic purposes. The produced biological effects are related
both to the intensity and frequency of the ultrasound wave used [1].
Compared to other external stimuli, it has good tissue penetration
capability, it is quite safe to human health and shows low operation and
instrumental costs [9,10]. Ultrasound represents an important tool for
imaging and diagnosis, in a technique called sonography. In particular,
the ultrasonic waves are focalized at a particular depth of diagnostic
interest. Owing to the different acoustic resistances of the various tis-
sues, the scattered signal is recovered, allowing to the imaging re-
construction of the different tissues. To enhance the echogenicity and
ultrasound responsiveness of certain tissues, microbubbles were de-
veloped as contrast agents. They basically consists of various gases
enhancing echogenicity stabilized within a lipid or protein shell
[11,12]. It is thus possible to obtain 2D and 3D images of tissues and
organs [3].
Furthermore ultrasound was used for the treatment of numerous
pathologies [13], such as a remedy of soft tissue injuries, for the ac-
celeration of wound healing, for the resolution of edema, or for the
softening of scar tissues [14]. Lithotripsy procedures were applied for
stones removal in urology [15]; low-intensity pulsed ultrasound found
therapeutic applications for bone growth stimulation [16]. Ultrasound-
assisted lipolysis and liposuction are conventional practices in cosmetic
surgery for fat tissue removal [17]. However, these topics are out of the
interest of the present work and the reader could refer to recent gold
reviews elsewhere [18,19].
This review will focus on the use of ultrasound in the presence of
both soft and solid-state nanoparticles (NPs) against tumor cells or
tissues and with a special emphasis on the sonodynamic treatment
(SDT). A very recent review in the field related either to NPs and na-
nomaterials used for SDT was reported [20]. A second review more
focused on the mechanisms of SDT related to experimental medicine
and biology was also recently written [21]. Here our aim is to propose
an update of the most recent advances in the field focusing on the
mechanisms underlying the synergistic effect of NPs and acoustic fields
toward the improved sonodynamic therapeutic outcome.
2. Sonophoresis
With respect to other routes of administration, transdermal drug
delivery has potential advantages since it reduces the first-pass meta-
bolism associated with oral delivery and is less painful than parenteral
administrations [22]. However, the stratum corneum limits passive
diffusion to small lipophilic molecules and methods to safely render it
permeable to ionic and larger molecules are needed [13]. The sono-
phoresis technique is based on the ability of ultrasound radiation to
increase the permeability of the stratum corneum, which is considered a
primary barrier to protein and drug diffusion [23]. Once a drug has
traversed the stratum corneum, the next layer is easier to perfuse, and
subsequently the drug can reach the capillary vessels to be absorbed
[13].
While ultrasound over all the frequency ranges can enhance skin
permeability, the physical mechanisms responsible for enhanced per-
meation are different in each regime. Initial studies focused on High
Frequency ultraSound (HFS) as the first use of ultrasound to deliver
therapeutics across the skin in 1954. Because the skin penetration depth
of the ultrasound waves is inversely dependent to the frequency of the
pressure wave, thereby its effect are limited on the stratum corneum at
high frequencies [24,25]. The characteristic permeation enhancement
achieved with HFS is one to ten-fold more with respect to the absence of
ultrasound [26]. In contrast, the enhanced transdermal permeation of
Low Frequency ultraSound (LFS) was only discovered later. Mitragotri
et al. reported that the in-vitro use of 20 kHz ultrasound resulted in
1000- times greater permeability for salicylic acid and sucrose across
human cadaver skin compared with that achieved with 1MHz ultra-
sound [27,28].
There are several mechanisms to enhance skin permeability in so-
nophoresis. Among these, the acoustic cavitation [29,30], the thermal
effects [27,31], the radiation forces and convection (acoustic streaming
and the resulting boundary-layer reduction) [32], as well as the lipid
extraction [33] were investigated.
One of the dominating mechanism for the enhancement of skin
permeability is acoustic cavitation [26,34]. With respect to stable ca-
vitation, the inertial cavitation results in higher permeability en-
hancement of the stratum corneum in ultrasound-assisted skin per-
meabilization [26]. The bubbles diameter that initially nucleate is
inversely proportional on ultrasound frequency. At high frequencies,
the nucleating bubbles are small (the diameter is circa 5 μm at 1MHz)
and can nucleate within the stratum corneum, giving rise to some dis-
ruption of this ordered structure. However, when using LFS, the nu-
cleated bubbles are too large and can no longer oscillate within the
stratum corneum (at 20 kHz the size is around 300 μm, that is much
larger than the 20 μm thickness of the stratum corneum). Using LFS, the
large bubbles form outside the skin, become unstable and implode
powerfully near the solid stratum corneum surface resulting in a jet of
fluid, referred to microjet. When these microjets affect the stratum
corneum, they erode the dead cells and help to permeate the membrane
[35–37]. Tang et al. definitively demonstrated by an experimental
study that ultrasound-induced cavitation is the key mechanism via
which LFS permeates the skin. They reported that cavitation, occurring
outside the skin, plays the pivotal role in the skin permeation effect,
while internal cavitation has no effect in the skin permeability [38].
Focusing on the NPs-assisted ultrasound as the aim of this review, a
first study supporting the delivery of oligonucleotides by the applica-
tion of LFS (20 kHz, 2.4W/cm2, 50% duty cycle, 10 min) across the full-
thickness pig skin was reported by Tezel et al. [39]. Similarly, Tran
et al. delivered small interfering RNA loaded into cationic liposomes to
melanocytic tumors present in skin to retard melanoma development.
Low-frequency ultrasound supplied by a four-cymbal transducer array
(20 kHz, 20% duty cycle, 15min) enabled the penetration of nanoli-
posomal-siRNA complexes throughout the epidermal and dermal layers
of laboratory-generated or animal skin. Nanoliposomal-mediated siRNA
targeting of (V600E)B-Raf and Akt3 led to a cooperatively acting circa
65% decrease in early or invasive cutaneous melanoma compared with
inhibition of each singly with negligible associated systemic toxicity
[40].
3. High intensity focused ultrasound
High intensity focused ultrasound (HIFU), also called focused ul-
trasound surgery (FUS) [5], is a non-invasive method where high in-
tensity ultrasonic waves are applied locally in a focal zone. The major
effect is an extreme temperature rise (greater than 80 °C) due to the
absorption of the ultrasound energy [7,41]. This increment results in a
complete and irreversible cell death through coagulative necrosis in the
focal region, minimizing the possibility of thermal damages to the tis-
sues outside the irradiated region [1]. Non-thermal effects as acoustic
cavitation, microstreaming and radiation forces also occur [8] inducing
shear stress causing membrane damage and cell death [7]. With a dif-
ferent modulation of exposure time, number of pulses and duty cycles it
is possible to obtain predominantly thermal or non-thermal effects in
the focal region [41], limiting i.e. temperature increase [43].
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HIFU was investigated for the treatment of various types of primary
solid tumors and metastasis, including prostate, breast, kidney and
liver. Moreover, HIFU was also proposed as a novel approach capable to
ablate heart ectopic foci and to obtain hemostasis in acute traumatic
injuries [7] and for the treatment of Alzheimer disease [43]. HIFU was
also successfully used to promote the uptake of various molecules, as
antineoplastic drugs, antibodies, genes and others [44], increasing
temporarily the cell permeability, thanks to the capability of ultrasound
to temporarily increase the cell permeability [8,45], as described more
in details below. Moreover, a possibility is to enhance the drug release
in a target region using HIFU by disrupting the drug trapping vesicles
[46].
Despite of many promising outcomes, there are some limitations to
this therapeutic approach. In particular, the achievement of elevated
temperatures when the region of interest is deep or hypervascularized
can be problematic. Actually, a solution could be to enhance the
acoustic power or the exposition time, however it would increase the
risk of side effects, as skin burns and nerve injury [47,48]. Thus, various
types of micro and nano–bubbles [49], as well as other particles [50],
were proposed in combination with HIFU for therapy and diagnostic
imaging. These structures are indeed able to enhance HIFU-associated
mechanical effects, providing cavitation nuclei [48]. Furthermore, they
increase the acoustic attenuation with a consequent temperature rise
[51], reducing the ultrasound intensity and the exposure time required
to obtain bioeffects [47].
4. Sonoporation
This ultrasound-based permeation technique allows for the transfer
of molecules between the intra- and extra-cellular medium [52–54].
Actually ultrasound can be used to temporarily render permeable the
cell membrane allowing for the uptake of drugs, DNA and other ther-
apeutic compounds from the extracellular environment [55]. Several
sonoporation mechanisms were proposed and the main hypotheses of
trapped microbubble interaction with cells are the push and pull me-
chanisms, micro-jetting, micro-streaming, and, more recently, transla-
tion of microbubbles through cells. Since the membrane alteration is
transient, it leaves the drug trapped inside the treated cells after soni-
cation.
Even if the biophysical mechanism that results in the enhancement
of the cell membrane permeability under ultrasound needs further
elucidation, it was reported that sonoporation is not due to inertial
cavitation, but to micro-streaming and shear stresses related to stable
oscillations [56,57]. In in-vitro experiments the dissolved gas in the
culture medium is sufficient so that the sonication itself generates ca-
vitation bubbles. Sonoporation is thus induced. In contrast, in in-vivo
applications the lungs are very efficient at clearing out small bubbles
from the circulatory system. Therefore micro and nanobubbles have to
be added to induce sonoporation through ultrasound irradiation [58].
In oncological research several in vitro studies have shown ultra-
sound-induced membrane permeability. This mechanism has increased
the uptake of anti-cancer drugs such as bleomycin, adriamycin, [59,60]
and cisplatin both in-vitro and in-vivo [61].
Moreover, transcranial delivery by low-frequency ultrasound can be
employed to temporarily disrupt the blood brain barrier (BBB) and thus
enhance drug diffusion through microbubbles [62]. Administration of
microbubbles further reduces the intensity threshold for temporarily
BBB disruptions, thus allowing for much lower and safer frequencies to
be applied than in their absence [63]. The targeted BBB disruption
could also support the delivery of chemotherapeutic agents for brain
tumors, which normally do not penetrate the BBB. More specifically,
the delivery of liposome-encapsulated doxorubicin to the BBB was first
investigated. The treated regions showed significantly higher con-
centrations of doxorubicin than the contralateral side. Moreover, the
concentration of the drug in the brain tissue was observed to growth
linearly with increasing the microbubble concentration [64].
Beside the use of sonoporation with chemotherapeutic molecules,
this method is particularly suitable for the delivery of free nucleotides,
which are otherwise prevented to cross the plasma membrane due to
their negative charge and large size [57,65]. Efficient gene transfer by
sonoporation was achieved when the applied ultrasound frequencies
are close to those used clinically. Typically they extend from 0.5 to
4MHz. Significant results were obtained in-vitro as well as in-vivo with
focused ultrasound [66]. The level of gene expression reported after
sonoporation treatments is one or two orders of magnitude higher than
the level obtained with plasmid DNA alone. However, it remains lower
than that obtained with chemical vectors [67]. This limitation is
probably ascribable to the main difficulty in the field of ultrasound-
assisted gene delivery. It consists in the lack of homogeneity both in the
sonication set-up and of the acoustic conditions.
5. Ultrasound-triggered drug delivery system
Biological systems have demonstrated very high spatiotemporal
(location and timing) sensitivity to cues and drugs. Polymer-based drug
delivery systems are able to achieve a constant rate of release. Moreover
they have been extensively studies for attaining localized and sustained
release of bioactive molecules [68].
Recently Huebsch et al. proposed a quasi-digital ultrasound-trig-
gered drug release, which could be accelerated and then switched back
off, on demand, by applying ultrasound to disrupt ionically cross-linked
hydrogels [69]. They reported that ultrasound does not permanently
damage these materials. In contrast these hydrogels are able to self-
repair the cross linked structure and to stop the release in the absence of
the ultrasound stimulus. In-vitro studies demonstrated that a tempo-
rally short, high-dose “bursts” of drug exposure could be applied to
enhance the toxicity of mitoxantrone toward breast cancer cells. Fur-
thermore, the authors used the developed hydrogel system in-vivo to
treat xenograft tumors with mitoxantrone. They found that daily ul-
trasound-stimulated drug release significantly reduced tumor growth
with respect to the sustained drug release alone. They envisioned that
the ultrasonically-assisted digital drug release will be applicable to a
broad variety of polymers and bioactive molecules. This can be a po-
tentially useful tool for studying how the timing of factor delivery
controls cell fate in-vivo.
To reduce the detrimental side effects of toxic chemotherapeutic
drugs, the ultimate strategy is to encapsulate the drugs in a vehicle
(either an organic or inorganic micro or nano-sized carrier) showing a
very low leak rate in circulation. At the same time, the carrier shows a
rapid release of the drug once inside the tumor, also limiting the
healthy tissue exposure [70–72].
Designing a vehicle with these two opposing properties is one of the
major challenge in the field of drug delivery [73–75]. Furthermore, the
design of a triggering strategy able to change the vehicle from its stable
yet circulating state to its unstable thus release state can be problematic
[57,76]. A unique mechanical actuation trigger is achieved by ex-
ploiting the size changes that occur when microbubbles (1–10 µm in
size) interact with ultrasound allowing for rapid drug release and fa-
cilitating delivery into nearby cells. It is thus possible to focus the ul-
trasound to just a few cubic millimeters, allowing for precise control
over the tissue location where the microbubbles are destabilized, yet
able to deliver the encapsulated drug. Moreover, performing drug de-
livery from microbubbles by using ultrasound as trigger gives the pos-
sibility to visualize the drug-loaded microbubbles by low-pressure ul-
trasound [77,78]. Actually, microbubbles were born as ultrasound
contrast agents and this promising technique is called “image-guided
drug delivery” [79].
Different strategies were proposed to load drugs into microbubbles
including drug molecules incorporated inside the hydrophobic shell,
shell electrostatic binding, and drug-containing liposomes linked to the
surface of microbubbles. For example, Tinkov et al. reported a 12-fold
increase in local drug concentration of doxorubicin-shell-embedded
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microbubbles and a significant reduction in tumor growth [80]. Simi-
larly, microbubbles loaded with 10-hydroxycamptothecin into the shell
and exposed to ultrasonic excitation showed a significant drug accu-
mulation in tumor tissues and a remarkable increase in tumor inhibition
rate [81]. Docetaxel-loaded microbubble demonstrated to be both an
effective ultrasound contrast agent in-vivo and enhanced the antitumor
drug capability in-vitro. In fact, by exposing to ultrasound microbubbles
loaded with doxorubicin-liposomes, twice more melanoma cells were
killed compared to doxorubicin-liposomes alone [82]. In addition to the
aforementioned small chemotherapeutic molecules, also therapeutic
nucleotides (genes and siRNA) were loaded into microbubbles [83]. For
example, siRNA-loaded microbubbles exposed to 1MHz ultrasound
were able to knockdown twice more the tumor suppressor gene PTEN
than control siRNA alone [84].
Endo-Takahashi et al. developed polyethyleneglycol (PEG)-modified
bubble liposomes containing ultrasound-contrast gas. Inside them, the
authors entrapped pDNA or siRNA to be simultaneously used for ul-
trasound imaging and gene delivery, thus useful in the field of ther-
anostics [44].
The main limitation to the use of microbubbles is due to their di-
mensions: being generally above 1 µm, it is expected that they do not
extravasate into tumors, since the interstices between tumor-associated
endothelial cells are in the range of 500 nm [85]. In order to avoid this
drawback, “nanobubbles” small enough to extravasate through these
endothelial gaps were proposed. More detail on this topic will be de-
scribed in the section below.
6. Sonodynamic therapy
Sonodynamic therapy (SDT) emerged more recently as a novel ap-
proach for the treatment of cancer. It is based on the use of low-in-
tensity ultrasound and a molecule, called sonosensitizer, that is soni-
cally activated [86]. Although SDT therapeutic efficacy has been
extensively demonstrated, the exact working mechanism is still under
debate and will be further discussed below. Sonosensitizer could be
activated by light through the sonoluminescence process [9] or with
pyrolytic reactions, or upon the increase of acoustic cavitation effects
[87]. SDT derives from the photodynamic therapy (PDT), where the
light (typically in the ultraviolet range) is used as an external stimulus
to activate a photosensitizer. However, the recognized advantage of
SDT over PDT is the higher tissue penetration depth [1,88]. A scheme of
both approaches is depicted in Fig. 1.
Many molecules were employed in SDT, such as porphyrins, some
antitumor drugs and various types of NPs [86,89]. It is also been re-
ported in literature the use of microbubbles as adjuvant for the sono-
sensitizers: these can be employed both as carrier of molecules and as
contrast agents for imaging purposes. Moreover, microbubbles can
enhance thermal effects, perturbing the tumor vasculature [90].
6.1. NPs used in the sonodynamic therapy
As stated above, SDT implies the synergistic effect of a non-toxic and
selective chemical agent, termed as sonosensitizer. The sonosensitizer is
activated by low-intensity ultrasound to produce ROS.
The majority of sensitizers investigated in early SDT studies were
porphyrin-based molecules or xanthene dyes, since they were originally
employed in PDT. They present a comparable ROS-mediated cytotoxic
effects when stimulated by ultrasound [21]. Nevertheless, most of these
sonosensitizing agents are strongly hydrophobic, i.e., they easily ag-
gregate in physiological environment, which can decrease their effec-
tiveness and negatively affect their pharmacokinetic behavior [92]. In
addition, these molecules can be toxic in some cases and show a low
selectivity toward cancer tissues [1]. This wide biodistribution can
seriously limit the clinical application of sonosensitizers. Actually, if the
concentration gradient between the diseased tissue and adjacent
normal tissues is not sufficiently high, is impossible carry out the SDT
without causing undesired side-effects. In order to overcome such cri-
tical issues, the application of various type of solid and soft micro- and
nano-particles in combination with SDT shows a great potential [93].
Thanks to their large surface area suitable for chemical modification
and functionalization, NPs can show an improvement of biocompat-
ibility, biodistribution and selectivity towards diseased tissues [20].
Moreover, the presence of particles in a liquid provides nucleation sites
for cavitation bubbles, lowering the cavitation threshold and thus en-
hancing the SDT efficacy [94]. An accurate description of the me-
chanisms involved in the sonodynamic approach is given further below
in this review.
This paragraph briefly mentions the researches developed in the last
decade about NP-assisted ultrasound therapy. Depending on the func-
tion assumed in the SDT, NPs can be classified as nanosensitizers or
vehicle carrying the sonosensitizer.
Liposomes-based delivery systems can be classified in this last ca-
tegory since they can reach the target tissue without losing their pay-
load when circulating in the body. Liposomes are created by self-as-
sembling lipid bilayer arrays, which separate hydrophobic and
hydrophilic regions. Therefore, they can carry a huge variety of sono-
sensitizers, therapeutic agents, genes, proteins, peptides, as well as
contrast agents. For this reason, they can be exploited for both diag-
nostic and imaging purposes under ultrasound irradiation [76,95].
In different studies [96,97], a lipid monolayer characterized by
hydrophobic tails and hydrophilic head groups, was used to stabilize
the microbubbles in the physiological environment. The lipid layer also
permitted the release of the hydrophobic payload in the diseased tissue
by exploiting the fragmentation of the monolayer when the internal
microbubble is exposed to ultrasound irradiation (Fig. 2). For example,
the study of Ibsen et al. [97] was focalized on the fabrication of per-
fluorocarbon (PFC) gas microbubble surrounded by a lipid monolayer.
The stability of these microbubbles and their ability to encapsulate the
doxorubicin drug were evaluated.
Unfortunately, the attachment of sensitizer drugs or contrast agents
on the lipidic surface can produce the instability of the particle. To
overcome this issue, polymeric poly(L-lactide-co-glycolide) (PLGA)
microbubbles were proposed [98]. Actually, PLGA microbubbles con-
jugated with rose bengal (RB) sensitizer resulted to be more stable than
the lipid counterparts. The stability of the structures were evaluated not
only in the physiological environment but also in the presence of ul-
trasound treatment. Indeed, while lipid-coated microbubbles were no
more detectable after 24 h in the physiological environment, PLGA
microbubbles resulted stable and they could be stored at 4 °C for a long
period with a minimal loss number. Finally, when conjugated with RB
sensitizers, PLGA microbubbles under ultrasound treatment exhibited a
selective cytotoxicity in-vitro and in-vivo experiments [98].
Another study developed polymethyl methacrylate (PMMA) NPs to
load the meso-tetrakis (4-sulfonatophenyl) porphyrin (TPPS) to form a
new sonosensitizing agent [99]. The results of the study demonstrated
that the TPPS loaded into PMMA NPs acted a major effect in the tumour
suppression than the free TPPS in solution. This effect is due to the
surface charge on NPs ensuring an enhanced cellular uptake. TPPS NPs
not only operated as sonosensitizer vehicle, but also enhanced the ca-
vitation activity.
In order to provide a safe delivery system, different researches
[100–102] focused on the manufacture of chitosan nanobubbles. Chit-
osan, a natural polysaccharide, was chosen for fabricating the nano-
bubble shell because of its high compatibility, low immunogenicity and
low toxicity. the core of the nanobubble consisted of perfluoropentane.
Chitosan nanobubbles had a unique polyvalent positive-charged prop-
erty, so they could complex DNA. They were thus exploited as DNA-
delivery systems to reach the target tissue when nanobubbles under-
went to ultrasound treatment. The same nanoconstruct was studied to
deliver oxygen to hypoxic tissues, exploiting the boiling point of the
perfluoropentane core (32 °C). In fact, whereas this compound is liquid
at room temperature, it is in vapour phase at body temperature, leading
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Fig. 1. Schematic overview of both photodynamic therapy (PDT) and sonodynamic therapy (SDT) against cancer. The photo- or sonosensitizers are administered systematically or locally
into the tumor tissue. They are then activated by either ultraviolet light or ultrasound radiation, respectively, leading to cancer tissue regression, or in the best-case scenario, eradication.
Reprinted under a Creative Commons License. Copyright 2017 The Author(s) from Ref. [91].
Fig. 2. Scheme of the possible mechanism of SDT assisted by microbubbles (MBs) loaded with organic sonosensitizer molecules. The MBs are injected in the blood stream and can
accumulate in the tumor tissue. Upon the ultrasound stimulation, the MBs produce cavitation and thus sono-luminescence emission and pyrolysis reactions. Thanks to the organic
sonosensitizer molecules included in the MBs, the formation of highly cytotoxic reactive oxygen species (ROS) and singlet oxygen (1O2) take place, leading to cancer cell death. Reprinted
with permission, Copyright 2016, John Wiley & Sons Inc. [89].
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to an higher expansion of the nanobubbles and enhancing the release of
loaded oxygen molecules under ultrasound irradiation [102].
In addition to liposomes and polymeric NPs, also metallic and in-
organic nanoconstructs could represent efficient platforms for carrying
sonosensitizer molecules. For example, gold NPs conjugated with pro-
toporphyrin IX and ultrasound irradiation showed a significant in-
hibitory effect on colon carcinoma in BALB/c mice [103]. Previous
studies [104] demonstrated that the presence of gold NPs prolong the
non-radiative relaxation time of protoporphyrin IX, promoting the
generation of singlet oxygen. Moreover, gold NPs facilitate the uptake
of the sonosensitizer molecules into tumoral cells and increase the ca-
vitation rate, acting both as cavitation nuclei and promoting the col-
lapse activation of such cavities [103].
Other studies also indicated the possibility of employing gold NPs
without the addition of sensitizing agents, acting themselves as nano-
sensitizers and carrying out the therapeutical action when activated by
ultrasound (Fig. 3). In this case, the NPs acted as sources of nucleation
sites, enhancing the inertial cavitation rate in biological environment,
and the minor resistance of cancer cells to physical stress is exploited
with respect to healthy ones [105]. A recent study [106] on gold NPs,
functionalized with PEG and folic acid and activated with ultrasound,
showed a promising reduction in cancer cells growth, accompanied by a
significant generation of ROS species. Sazgarnia et al. [107] also found
that the combination of gold NPs, ultrasound and intense pulsed light
was a good strategy to further improve the therapeutic effect on tumors.
In fact, the combination of these stimuli can cause a rapid heating and a
subsequent vaporization of the surrounding medium, contributing to
lower the cavitation pressure [108].
Similar considerations can be done about porous silicon NPs that
present a good sonosensitizing efficiency, both in-vitro and in-vivo,
combined with other interesting advantages, such as low toxicity, bio-
degradability and chance for targeting functionalization [109]. The
observed decrease of cavitation threshold in the presence of porous
silicon NPs was explained by the presence of nano-sized nucleation
centers due to the roughness of particle surfaces [110]. The authors
pointed out that this mechanism was also favoured by the presence of
Fig. 3. (A) BEAS-2B normal lung cells and A549 lung cancer cells after US treatment with gold NPs and the corresponding control cells (untreated with or without US or NPs). (B) MCF-
10A normal breast cells and MDA-MB-231 breast cancer cells with/without US treatment and super-paramagnetic iron oxide NPs and the corresponding control (untreated) cells
*represents P < .05, **represents P < .01, ***represents P < .001. (C) TEM images of H-184B5F5/M10 normal breast cells (a–c) and MDA-MB-231 breast cancer cells (d–f) cells, where
a and d are control samples; b and e correspond to cells treated with US; c and f show the cells after combined treatment with US and magnetic NPs [105].
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residual air bubbles inside the silicon nanoporous structure and by the
formation of gas (hydrogen) bubbles due to silicon NPs’ dissolution
[110].
Nevertheless, concerning the class of NPs employed as nanosensi-
tizers in SDT, the most widely studied are titanium dioxide (TiO2) NPs.
TiO2, thanks to its semiconducting properties, is commonly used as
photosensitizer in PDT to obtain ROS-mediated cytotoxicity. More re-
cently, several studies [91] highlighted the possibility to activate ROS
formation through ultrasound irradiation. In this case the ROS pro-
duction may be triggered by several mechanisms [111], as also sche-
matized in Fig. 4 TiO2 particles provide additional nuclei that increase
the formation of ultrasound-induced cavitation bubbles. The bubble
collapse induces locally high temperature increase able to generate OH
radical via water pyrolysis. Moreover, thermal excitation and photo-
excitation of TiO2 by sonoluminescence, resulting from bubbles im-
plosion, also can lead to the formation of OH radicals [111]. Further-
more, TiO2 conjugation with noble metals can strongly increase the
catalytic activity of the material [112]. Important therapeutical im-
provements are obtained with TiO2 NPs’ functionalization with tar-
geting molecules (such as folic acid [113], avidin [114] or pre S1/S2,
part of the L protein from the hepatites virus [115]). These studies
reported an enhanced and preferential binding and internalization of
NPs toward cancer cells, auspicious for the development of a more
targeted therapy.
Relying on these promising results, NPs made of semiconductor
metal oxides (e.g. TiO2 and ZnO) are believed to play in future a crucial
role in medicine as photo- or sonosensitizers for cancer therapy [91].
Another class of metal oxide NPs that can be used in combination
with ultrasound are magnetic NPs, such as magnetite (Fe3O4) or ma-
ghemite (Fe2O3) (Fig. 3). A recent study [116] indicated a synergistic
effect of Fe3O4 NPs with low intensity ultrasound, causing an increase
in ROS production. Indeed, it is believed that the ultrasound irradiation
enhances the release of iron, necessary to trigger the Fenton reaction,
responsible of the ROS generation.
A collection of the various nanomaterials used for performing SDT
in-vivo on mouse models and the sorted therapeutic effects are reported
in Table 1.
6.2. The mechanisms of NP-assisted SDT
In the past twenty-five years, a great amount of research focused on
SDT as a promising cancer therapy thank oto reduced side effects and
high penetration-depth. However, the deep understanding of the me-
chanisms behind its cytotoxic effects is still lacking. Indeed, the exact
physical/chemical mechanisms remain unclear while the SDT ther-
apeutic efficacy, based on the combination of ROS generation and
mechanical cytotoxic effects, has been extensively demonstrated [89].
This can be attributed to the complexity of the SDT process, involving
together physical, chemical and biological reactions. However, since
the first work on SDT by Umemura et al. in 1989, several steps towards
the understanding of SDT were made.
For the purposes of this review, NP-assisted SDT will refer to the
“NP-dependent sonochemical or sonophotochemical events in an
acoustic field leading to cytotoxicity”, as referenced in [21]. This de-
finition highlights the key role played by the NPs in inducing the cy-
totoxic effects, as initiators of the SDT process. Therefore, we will in-
itially review the literature related to the interaction between NPs and
acoustic field in aqueous environment, such as the human body. Then,
we will discuss the possible processes leading to the observed cytotoxic
effects. The final aim is to possibly clarify by which mechanisms can the
NPs induce cytotoxic effects in an acoustic field.
6.2.1. NP interaction with ultrasonic waves
SDT uses ultrasound at relatively low intensities (ranging from 0.5
to 4W/cm2) that are not able to induce thermal or mechanical effects to
living cells, thus they are regarded as safe. Much higher intensities are
needed to cause cytotoxic effects such as temperature increase and/or
inertial cavitation inception (such in the case of HIFU, as discussed
above). Alternatively, high-energy shock-waves can be used to mini-
mize the temperature effects while increasing the likelihood of cavita-
tion [93]. Indeed, using single acoustic pulses with a wide frequency
range (up to 20MHz) and high-pressure amplitude (up to 120MPa)
Fig. 4. Scheme of the possible mechanisms in metal oxide nanoparticles (i.e. titanium dioxide, TiO2, or zinc oxide, ZnO, nanoparticles NPs) to generate reactive oxygen species (ROS) in
water-based media. Here both ultraviolet (UV) and ultrasound radiations are depicted as a source to generate ROS at the surface of semiconductor metal oxide NPs in water. In particular,
the ultrasound produces cavitation bubbles that, during their collapse, emit the sonoluminescent light. As a result, the semiconductor NPs are photo- or sono-excited, injecting electrons
(e−) from valence to the conduction band, leaving the holes (h+) in the valence band. The separated e− and h+ react with water and gas molecules adsorbed on the semiconductor
surface, generating the ROS (%O2−, %OH, H2O2). Moreover, the radiative recombination of electron-hole pair can lead to a photon emission able to generate singlet oxygen (1O2) from the
oxygen molecules (O2). Reprinted under a Creative Commons License. Copyright 2017 The Author(s) from Ref. [91].
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combined with porphyrins-loaded polymeric NPs, Canaparo et al. were
able to induce sonodynamic therapy effects on an in-vitro neuro-
blastoma model [99]. As stated above, the inertial cavitation refers to
the rapid growth and violent collapse of bubbles after exposure to ul-
trasound. As ultrasound wave travels through a liquid/tissue, any gas
bubbles in the liquid are forced to oscillate in the applied acoustic field.
Increasing acoustic pressure, this oscillation becomes unstable and
eventually the bubble implodes, generating extremely high tempera-
tures and pressures at the center of the collapsing bubble [21]. This may
be viewed as a nanometric sonochemical reactor, able to generate ROS
by the homolytic cleavage of water molecules or to induce chemical
changes close and/or inside the imploding bubble [118]. The minimum
ultrasound intensity able to generate inertial cavitation is called cavi-
tation threshold, and this is dependent on the characteristics of the ir-
radiated medium, such as the viscosity, presence of impurities and
temperature [119]. As reported already in some example above, it has
been largely demonstrated that the presence of NPs in aqueous solu-
tions decreases the cavitation threshold [110]. NPs are indeed able to
stabilize nanobubbles on their surface and inside well-defined cavities
[120–123]. These nanobubbles can initiate acoustic inertial cavitation
acting as cavitation nuclei. In the context of SDT, when actuated with
low-intensity ultrasound, NPs can thus initiate inertial cavitation inside
and/or in close vicinity to the target cell and consequently elicit cyto-
toxic effects. It is indeed now generally accepted that inertialcavitation
is the key mechanism behind the therapeutic effects of SDT [9].
Therefore, future research aiming at increasing the NPs-assisted STD
efficacy should primarily focus on improving the ability of NPs to in-
duce inertial cavitation. Along these lines, Yildirim et al. [124] studied
the effects of the NP surface chemistry on the efficiency of inertial ca-
vitation initiation: they showed that a rough, hydrophobic NP surface is
needed to preserve the surface nanobubbles and to efficiently induce
inertial cavitation. Exploiting these findings, the authors synthesized
100 nm nanoparticle ultrasound agents based on phospholipid-coated,
mesoporous, hydrophobically functionalized silica nanoparticles that
stabilized gas nanobubbles at their surface even once internalized by
cancer cells. These ultrasound agents produced cavitating bubbles only
when subjected to non-toxic levels of HIFU, leading to cancer cells
death by cellular membrane destruction [48]. Using a different ap-
proach to increase the stabilization of nanobubbles on NPs surface,
Kwan et al. [125] developed a novel ultrasound-responsive single-
cavity polymeric NP, called nanocup, able to trap and stabilize gas
nanobubbles thanks to its innovative surface morphology. Under ul-
trasonic irradiation, these single-cavity NPs initiated and sustained the
cavitation activity four times longer than the existing microbubble
constructs, leading to the enhanced delivery of therapeutics in tissue
model (Fig. 5). Mesoporous silica NPs with hydrophobic internal na-
novoids were developed by Zhao and co-workers [126]. In combination
with safe low-energy US (below 1W/cm2), these mesoporous NPs lead
to effective breast cancer cells killing due to acoustic cavitation initia-
tion. In view of the above, further research is expected toward the
development of efficient cavitation-promoting NP-sensitizers- for SDT.
6.2.2. Mechanisms leading to the SDT therapeutic effect
Once the role of acoustic cavitation was defined as the first me-
chanism behind NP-assisted SDT, the possible processes leading to the
final therapeutic effect are reviewed in the following. We distinguish
between cytotoxic effects deriving directly from the collapse of the
cavitating bubble and cytotoxic effects arising from the activation of the
nanoparticles by cavitating bubbles.
6.2.2.1. Direct cytotoxic effects of cavitating bubbles. As discussed above,
the imploding bubble can be considered as a nano-sonochemical reactor
able to generate ROS in the presence of water and oxygen. These
unstable molecules can exert high cytotoxic effects if generated
intracellularly, such as oxidative stress, DNA damage and apoptosis,
and can induce lipid peroxidation if generated close to the cell
membrane [127]. Several studies showed that specific ROS
scavengers such as histidine, mannitol and superoxide dismutase
(SOD) protect the target cells from the SDT therapeutic effect. Their
role strongly suggests an involvement of ROS in the SDT cytotoxic effect
[128,129]. Therefore, ROS generated during the collapse of cavitating
bubbles can be regarded as one of the possible mechanisms leading to
the therapeutic effect of SDT. In addition to the chemical effects of
cavitation, it was suggested that the mechanical effects arising from the
implosion of cavitating bubbles can play a key role in eliciting cytotoxic
effects. These mechanical effects comprises acoustic streaming, liquid
microjets and shock waves. They are generated by the collapse of the
cavitating bubbles and can mechanically damage cell membranes and
intracellular components. Moreover, if during the expansion phase the
intracellular bubble exceeds the volume of the cell, mechanical
destruction of the cell can be achieved [48]. In this regard, by
comparing the effects of SDT and PDT using the same photosensitizer,
Hiraoka et al. concluded that the enhanced ultrasound-induced cell
killing was mainly due to mechanical stress such as physical disruption
of cellular membranes [130].
6.2.2.2. Cytotoxic effects arising from nanoparticle-activation by cavitating
bubbles. Since NP-induced cavitation can be regarded as a mean of
focusing the externally applied ultrasound energy, it should be
considered the possibility that part of this energy could be transferred
to the NPs. Here, we will explore how cavitating bubbles can interact
with the sonosensitizer (i.e. the nanoparticle), activate it and finally
lead to cytotoxic effects.
One of the effect produced by cavitation is sonoluminescence (SL).
This is the emission of light from cavitating bubbles, and although the
exact mechanism is still under debate, it is now generally accepted that
it arises from the relaxation of excited chemical species during the
bubble collapse [131]. In the earlier reports on SDT by Umemura et al.,
the authors suggested a role for SL based on the observation that:
1. light emission could be achieved using ultrasound conditions that
were employed to elicit sonodynamic effects;
2. the used sonosensitizers, hematoporphyrin, was a photosensitizer
[132].
These authors assumed that light bursts emitted by cavitating
bubbles could be absorbed by the sonosensitizer and then, similarly to
the photodynamic therapy mechanism, the excited sonosensitizer
would generate an electron-hole (e-/h+) pair that subsequently gen-
erates ROS in aqueous environment. Moreover, Sazgarnia et al. [133]
succeeded in detecting SL in gel-based phantoms using protoporphyrin
IX coupled to gold NPs and thus showing that SL is effectively generated
during SDT.
Since metal-oxide NPs, such as TiO2 NPs, are able to work as pho-
tosensitizers for photodynamic therapy, several authors suggested that
the use of such NPs could improve the SDT efficacy exploiting sono-
luminescence as mechanism to generate cytotoxic ROS [115,134].
Deepagan et al., based on this hypothesis, functionalized TiO2 NPs with
gold NPs (Au-TiO2) in order to improve its quantum yield: this func-
tionalization increased the e−/h+ recombination time by trapping the
photoexcited electron while widening the absorption spectrum via
surface plasmon resonance. Compared to bare TiO2 NPs, the authors
showed that Au-TiO2 NPs generated a greater amount of ROS and lead
to complete suppression of tumor growth, in-vivo (Fig. 6) [135]. More
recently, Dai et al. [136] developed a novel nanoconstruct (NC) func-
tionalizing two-dimensional (2D) reduced graphene oxide (GR) with
TiO2 NPs (TiO2-GR NC). The high electroconductivity of graphene fa-
cilitated the separation of the sono-generated e−/h+ pairs leading to
higher ROS generation in-vitro. The SDT efficacy in-vivo was compared
to the bare TiO2 NPs. Being both Au-TiO2 and TiO2-GR NCs highly ef-
ficient in converting light into ROS, authors interpreted these results as
a consequence of the sonoluminescent excitation of the sonosensitizers.
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However, this phenomenon cannot be regarded as the only mechanism
behind the above-mentioned results. The size, morphology and surface
chemistry of the sonosensitizers have indeed also improved the ability
of TiO2 NPs to initiate acoustic cavitation by trapping more gas-nano-
bubbles at its surface. This would eventually lead to higher cavitation
activity, higher ROS generation and thus cellular toxicity. In this re-
gard, no report to date has definitely demonstrated the activation of
sonosensitizers by sonoluminescent light. The exclusive observation
that ROS are generated in SDT using photosensitizers (as metal-oxide
NPs) cannot be regarded as a conclusive evidence for the sonolumi-
nescent excitation of the sonosensitizer. Actually, ROS can be also
generated just by cavitating bubbles, as discussed in the previous
paragraph. In this context, it is worth mentioning that Riesz et al. [137]
excluded the involvement of SL in the sonodynamic activation of the
porphyrin-based sonosensitizer ATX-70 by studying the temperature
effect on ROS generation. Moreover, Hachimine et al. [138] suggested
that the contribution of SL to the SDT efficacy was not relevant, as this
sensitizer could not absorb light, but could exert high cytotoxic effects
to cancer cells under ultrasonic irradiation. Summarizing, from the
available data the contribution of SL to the therapeutic efficacy of SDT
has still to be fully clarified. Further research is needed to definitely
unravel its role as sonosensitizer activator.
The mechanisms leading to the ultrasound-dependent enhancement
of the cytotoxic action of sonosensitizers, such as porphyrins and or-
ganic dyes was reviewed by Misik and Riesz [118]. The authors sug-
gested that SDT cytotoxic effects are due to the chemical activation of
sonosensitizers inside or in the close vicinity to the collapsing bubbles.
As mentioned above, the heat released by the inertial confinement of
the gas in the collapsing bubble can either directly induce the pyrolysis
of sonosensitizer or make it reacting with cavitation-generated ROS,
eventually forming cytotoxic sensitizer-dependent free radicals. In view
of what stated above in the case of NP-assisted SDT, it can be hy-
pothesized that both cavitation-induced high temperatures and ROS
chemically activate the NPs. The collapsing bubbles are thus expected
to localize close to their site of origin, i.e. the NP surface. This could be
the case for ROS-responsive NP-based drug delivery systems or oxida-
tive stress responding NPs [139,140]. Moreover, acoustic cavitation can
induce mechanical activation of NPs, such as formation of a meso-
porous surface, structural modifications and the creation of fresh
highly-reactive metal oxide surfaces. These mechanical activation
modes can lead to a higher chemical reactivity of the sonosensitizing
NP and thus to a possible higher cellular toxicity [141,142].
6.3. Summary of nanoparticles-assisted SDT working mechanisms
A summary of the above-suggested mechanisms is shown in Fig. 7.
Fig. 5. (a) Schematic of the nanocup activation upon ultrasound exposure (b) TEM images, DLS analysis and acoustic pressure needed to generate acoustic cavitation are shown. (c)
Nanocups (here labeled as FNCs) penetration in a tissue model after US treatment, quantified as the average increase in fluorescence intensity of TRITCD profile taken down the center
line. SonoVue®: commercial contrast agent. Adapted with permission from [125].
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At first, the interaction of NPs with low-intensity ultrasonic waves can
generate acoustic cavitation. Then, the collapse of cavitating bubbles
can directly generate cytotoxic effects, both sono-mechanical, such as
shearing stresses and shock waves, and sono-chemical, as the formation
of cytotoxic ROS. Together with these mechano-chemical phenomena,
acoustic cavitation also induces the activation of the NPs leading to
further cellular damage. According to the most agreed theory, sonolu-
minescence could excite NPs in generating e−/h+ pairs and subse-
quently cytotoxic ROS, while shock waves and high temperatures could
change their chemical and/or structural properties possibly increasing
their cellular toxicity. Beside these effects, it is very complex to ex-
perimentally distinguish between the individual contribution of each
mechanism to the final STD therapeutic outcome. Actually, it can de-
pend on the type of the sonosensitizing NP, on the ultrasound para-
meters, and on the experimental setup. For these reasons the SDT needs
to be considered as a combination of different simultaneous
mechanisms.
6.4. The cytotoxic effects of sonodynamic therapy
The cytotoxicity of SDT is a challenging topic and the comprehen-
sion of the toxicity mechanisms is not simple. Actually, such mechan-
isms of toxicity are strictly dependent on the nature and characteristics
of both US and NPs and mostly influenced by the environmental con-
ditions. For example, different sonosensitizers, even if belonging to the
same category like metal oxide NPs, could behave differently in the
same experimental condition. In the same way, different US para-
meters, like frequency and intensity, could generate different responses
in the presence of the same sonosensitizer [87].
Usually, all studies of SDT demonstrated the toxicity of the treat-
ment showing the effects on the cell viability. This factor is checked in
different ways, through the detection of enzymatic activity (MTT, WST-
Fig. 6. (a) Schematic illustration of using Au-TiO2 NPs as
sonosensitizers for efficient tumor SDT. (b)
Diphenylisobenzofuran (DPBF) was used as fluorescent
probe for detecting the sonogeneration of singlet oxygen.
Gold NPs-functionalized TiO2 lead to higher ROS genera-
tion. (c) SDT therapeutic outcome in SCC7 tumor-bearing
mice. Hydrophilized Au-TiO2 NPs (HAu-TiO2 NCs) resulted
in tumor regression. Adapted with permission from [135].
Copyright 2016, American Chemical Society.
Fig. 7. Working hypothesis of the mechanism of SDT. The combination of US and NPs induces acoustic cavitation. This leads to cytotoxic effects via two main pathways: either collapsing
bubbles directly damage cells through shock waves, shear stresses and ROS, or the cavitation-induced NPs activation leads to chemical cytotoxicity.
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1, CellTiter Glo assay), the inhibition of cell growth (clonogenic assay)
and the cell lysis (Trypan Blue staining). Different works in the litera-
ture reported their individual explanations about the cell toxicity and
attributed it to numerous components of SDT-cytotoxic effects, as fur-
ther detailed in the following.
First, a pivotal role in SDT-induced cytotoxicity seems to be played
by the oxidative stress [143]. ROS are produced over the limits toler-
ated by the cells, leading to oxidative stress and oxidative lesions in the
cellular structures. The type of the induced cell death varies in the
different contexts and either apoptosis or necrosis are reported
[88,144]. The nature of the involved ROS depends on the method used
for their investigation (i.e. Electron Paramagnetic Resonance Spectro-
scopy – ESR, Flow cytometry, Spectrofluorimetry), the molecules used
for their detection (i.e. specific fluorescent and chemiluminescent sen-
sors, ESR spin traps or ROS scavengers) and experimental conditions
used (temperature, test duration). However, even if ROS are not easy to
be identified, their presence is confirmed by a plethora of observed
“ROS related” biological effects. These effects include the induction of
apoptosis, the lipids peroxidation, the loss of the mitochondrial mem-
brane potential, the DNA damage and the activation of different ROS
signaling pathways [87].
Among all the identified ROS involved in the SDT process, the most
discussed is the singlet oxygen radical. For Wang et al. it is considered
the predominant mediator in sonodynamic activity [88], while others
works support the idea that different types of ROS are involved in the
cytotoxic effect [118]. This oxidizing compound is possibly generated
by the action of sonoluminescent hotspots produced by the ultrasound
energy on the sonosensitizer [9]. The singlet oxygen presence is asso-
ciated with detrimental effects for cell viability like membrane and
cytoskeletal damage, DNA fragmentation and loss of mitochondrial
membrane potential [88,145].
The sonochemical effects associated to this highly reactive com-
pound and, more in general to ROS generation, are often detected in
association with other types of effects defined as sonomechanical ones.
These effects arise either from the US action on the aqueous medium
(bubble implosion and energy release) or from the direct interaction of
NPs with the cell structures. The result is a mechanical damage and a
consequent induction of cell death by the so called “mechanical
pathway” from refs. [88,105], as also depicted in Fig. 3.
As discussed in this review, the cell death induced by the combined
treatment of US and NPs is the aim of the nanoparticles-assisted SDT.
However, other than illustrating the cytotoxic factors of the SDT, the
following paragraph tries to give a more deep comprehension of the
effects related to the single agent. Actually, the application of SDT
implies the safety of each used component: neither the stimulus nor the
sonosensitizer are toxic, but when they are combined together a cyto-
toxic event occurs. Nevertheless, either US and NPs could become toxic
in specific conditions and only the comprehension of the uncombined
cytotoxicity mechanisms will make possible a more precise and fine
tuning of their synergistic cytotoxic effect. Here a special focus will be
given on metal oxide NPs, being the most interesting in terms of cyto-
toxic-related effects.
6.4.1. US-related toxicity
The ability of US to induce cell toxicity was largely demonstrated in
the literature and US-based therapeutic applications are currently used
in the clinical setting [146–149], as further detailed in the chapter 7 of
this review.
For instance, HIFU are able to generate thermal effects detrimental
for cell viability and find application in tumor ablation for cancer
therapy [7]. However, in the context of SDT only the cytotoxic effect of
low intensity US (below 5W/cm2) must be taken into account. The
intensity of the ultrasonic waves is a pivotal parameter for cytotoxicity,
and its variations, even in the range of low intensities, mediates dif-
ferent toxic effects in the biological systems. Umemura et al. [150],
investigated the toxicity profiles of different low intensity pulsed-US
(LIPUS) in a human leukemia cell line. They demonstrated that it is
possible to tune the cytotoxic effect by simply modifying the US in-
tensity. The authors thus identified an optimal condition for the gen-
eration of the apoptotic event only. Evidences of this behavior came
also from Tian et al. [143]. These authors demonstrated that the pro-
portion between cell apoptosis and necrosis could be determined by the
intensity of the US stimulus employed in the experimental setting.
Focusing especially on apoptosis, the association between US and
this death process is largely reported in the literature [151–155].
Nevertheless, the precise mechanisms driving this event are nor shared
neither completely understood. Prausnits and coworkers demonstrated
that Ca2+ plays a major role in the apoptosis and that this event is
induced by an increase of cytosolic Ca2+. This correlation emerged also
in other works and a partial explanation seems to lie in the mechanical
stress induced by US on the cell membrane. In particular, US treatment
is able to increase the permeability and pore formation in the plasma
membrane and to create membrane wounds. These events lead to a
Ca2+ intracellular influx and to its release from intracellular stores
[156,157].
The ability of ultrasound to generate a mechanical cell damage is a
challenging question. The main idea relates this event to two non-
thermal effects, classified as acoustic streaming and cavitation.
As mentioned above, the cavitation induced by US relies on the
formation of tiny gas bubble in the tissues as the result of US vibration
[158]. In this context, the damage to the biological structures is mainly
due to the inertial cavitation, where the bubble implosion results in an
aggressive process able to direct injury the cell structure (Fig. 8). Dif-
ferent mechanisms of damage are instead associated to the acoustic
streaming. This is the movement of a fluid due to an ultrasound wave,
generated by the energy transfer of the ultrasound to the fluid. It can be
the movement generated by the ultrasound beam propagation (bulk
streaming) or the eddies of flow around a vibrating bubble (micro-
streaming) [159]. In both cases this is a less aggressive process than the
cavitation itself. Furthermore, the sound waves are not strong enough
to produce a real cell damage, but just able to displace ions and mo-
lecules. The result is a possible rearrangement of biological structures
accompanied by fluid movements in the fluid around cell membranes .
Moreover, other than structural effects, low-intensity US cavitation
was demonstrated to produce alteration in the cellular activity, like the
protein synthesis and the cytokynes production [160]. This functional
effect can be explained by an activation of the mechanoreceptors able
to detect the mechanical stimulations produced by US [161]. This ac-
tivation could be also interpreted as a kind of “cellular recovery re-
sponse”, developed by the cell to fight the damages induced by the
treatment [162]. For instance, Xiong et al. recently demonstrated that
LIPUS activates pathways related to the cell proliferation in mesench-
ymal stem cells. Similarly, Ling et al. correlated the US treatment to the
proliferation signaling pathways of PI3K/AKT in human amnion-de-
rived mesenchymal stem cells [163].
Finally, the cytotoxic effect of ultrasound is not only related to
mechanical damages, but also to the production of toxic chemical
species, i.e. ROS (Fig. 8). These ROS could derive from the sonochem-
ical reactions induced by the inertial cavitation in the medium [164] or
could be intracellularly produced by the cellular mitochondrial appa-
ratus in a second moment. For this reason, in SDT one of the main role
of the sonosensitizer is to enhance the production of ROS induced by
the ultrasound treatment, even if the cell damage is due to the sy-
nergistic effect of these two components or just from ones, is already
under debate [156].
6.4.2. Metal oxide NPs toxicity
Several metal oxide NPs were shown to exhibit intrinsic cytotoxicity
both on prokaryotic and eukaryotic cells [165,166]. The mechanisms
involved in the cytotoxic effect are complex and difficult to generalize.
In fact, they are strictly dependent on the concentration and physico-
chemical properties of the specific metal oxides that also affect their
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behavior in the biological contest [167].
However, from all the proposed cytotoxicity mechanisms by the
literature, three of them merit consideration in the application of SDT:
(i) the generation of ROS; (ii) the mechanical destruction of cell
membranes; (iii) the metal-ion release.
For the first case, some works evidence the ability of metal oxides
NPs to produce ROS even in absence of any stimulus. In particular, for
elements or compounds belonging to the group of semiconductors, this
ability lies in their chemical structure. Electrons can easily migrate to
the particle surface where they react with the adsorbed species, leaving
extremely reactive holes in the conduction band. This mechanism seems
to be enhanced by the numerous defects in the NPs crystal structure
[168] and could be efficiently induced by the US stimulus in the context
of SDT [88]. Furthermore, ROS could derive from a more indirect
mechanism, involving the interaction between NPs and the electron
transport chain placed in the cell mitochondrial apparatus [169].
The second interesting mechanism associated to metal oxide NPs, or
even more in general to the presence of NPs, is the mechanical de-
struction of cell membranes [170]. Damages in the cell membrane due
to NP treatment are well reported in the literature [171]. Nevertheless
the precise toxicity mechanism is still under debate. Vidic and cow-
orkers explained that the point defects, such as atoms at edges, give rise
to an abrasive NPs surface able to the injury the cell membrane [172].
Despite the exact identification of the causes, this intriguingly effect can
be favorably exploited by SDT. In fact, the dissociation of NPs induced
by the ultrasound action could enhance the physical interactions with
the cell membrane leading to an increase of the cytotoxic effect [173].
Finally the metal-ion release due to the dissolution of metal oxide
NPs in aqueous media is frequently considered as the major or even the
only cause of metal oxide NPs toxicity [20]. The mechanistic causes of
this metal-associated toxicity are poorly explored and seems to be very
specific for each metal. For instance, the dissolution of ZnO NPs into
Zn2+ induces a mitochondrial-driven apoptosis and a protein dis-
equilibrium toxicity, due to the activation of specific different cellular
responses [174]. Also in this case, this characteristic metal oxide NP
effect could be exploited by SDT, being the metal ions release facilitated
by ultrasound stimulation [175].
7. Clinical applications of NPs assisted ultrasound in cancer
treatments
Ultrasound is the most commonly used imaging technique in clinics
[146]. Several contrast-enhanced ultrasound are clinically approved in
more than 50 countries, mainly in Europe, Asia and Canada with a
broad spectrum of applications [176]. In the last decade, microbubbles
(MBs) developed as ultrasound contrast agent (UCA) were also pro-
posed for drug delivery purposes via sonoporation [177]. MBs coupled
with ultrasound lead to the creation of pores in the cell membrane.
They can also open the endothelial junctions, thus enhancing vessel
permeability and improving the extravasation of co-administered
drugs. This technique is currently employed in different preclinical and
also few clinical trials [146]. The studies from Postema et al. and
Dimcevski et al. reported that phospholipidic MB (SonoVue®) in com-
bination with ultrasound can be successfully used to increase the re-
sponse of cancer patients to gemcitabine [147,178].
Ultrasound-based approaches were also adopted to facilitate drug
delivery across the blood–brain barrier (BBB) and a first clinical trial
(NCT02343991) has been started to evaluate the safety of BBB dis-
ruption in combination with lipidic MBs and magnetic resonance ima-
ging-guided ultrasound to enhance the accumulation of doxorubicin in
brain tumors [179].
Recently, nanoscale UCAs like nanobubbles, echogenic liposomes,
Fig. 8. Scheme of the various cell toxicity mechanisms induced by SDT. The cavitation induced by ultrasound produces micro-sized gas bubbles in the cell. Sonoluminescent light
radiation can be also produced. The sonosensitizer is excited and generate reactive oxygen species (ROS), which are also directly involved in the cellular toxicity. In particular, the
damage of mitochondrial membrane and the release of Cyt c, both mediated by ROS, induce the cell apoptosis. Reprinted under a Creative Commons Attribution-NonCommercial-Share
Alike 4.0 Unported License. Copyright 2016 Cancer Biology & Medicine [88].
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micelles and nanodroplets were proposed to overcome the size limit of
the MBs [146]. Indeed, in contrast to MBs, the above-mentioned na-
nostructures are able to extravasate from the blood vessels to the tissues
and transport the drugs deeper into the malignant cells, enabling new
theranostic capabilities. Although a lot of refinements concerning na-
noscale UCAs are currently ongoing and it is expectable a substantial
impact on future drug delivery field, their clinical translation has not
been initiated so far [177]. Doxorubicin-containing liposomes were
widely used in ultrasound-based drug delivery studies [146]. The
reason for their popularity in the research studies resides in fact that
several forms, known as Doxil, Caelyx, DaunoXome and Myocet, are
already clinically approved by FDA [180]. The engineering of these
liposomes for ultrasound-based applications requires an efficient drug
loading, stability during circulation, and efficient release of the cargo
upon insonation. For example, stable long-circulating liposomes con-
taining doxorubicin reduce drug-related toxicity, and liposome for-
mulations, where doxorubicin can be locally released by heat, are now
in clinical trials [78,181].
There are still few obstacles to translate the ultrasound-mediated
drug delivery from nanostructures to a clinical setting. For instance, the
comprehension of the cytotoxic mechanisms taking place in-vivo has
still to be clarified. Similarly, the biological effects will need to be
closely monitored and it will also be important to understand the bio-
distribution and pharmacokinetics of the NPs coupled with ultrasound
when delivered in-vivo [180]. However, advances in the field are in
progress as more in-vitro and in-vivo studies are being performed.
SDT has exhibited profound physical and chemical changes on cel-
lular structure. It has also shown notable efficacy against a variety of
neoplastic cell lines in both in-vitro and in-vivo studies (see a prominent
review elsewhere [149] on this topic). The optimization of sonosensi-
tizers with great sonodynamic efficiency and biocompatibility re-
presents a key issue for SDT clinical applications [21].
SDT has shown efficacy in both in-vitro and in-vivo against multiple
adherent neoplastic cell lines, with a particular promise against leu-
kemia cells. Nevertheless, at the clinical level the assessment of this
technique has been limited to solid tumors only [149].
X. J. Wang et al. employed a new sonosensitizing agent (referred
Sonoflora 1™ (SF1)) developed by SonneMed, LLC able to produce
singlet oxygen upon interaction with the proper ultrasound wave and
induce cellular necrosis. The authors reported preliminary in-vitro and
animal studies [182] and successively they published initial clinical
data using SDT with SF1 for the treatment of an advanced breast cancer
[183]. Three patients with metastasized breast carcinoma were studied.
Their carcinoma failed to respond to the conventional therapy and
spread to the whole body. The SDT agent was administered through
lingual absorption and a combination of sonodynamic and photo-
dynamic therapies was applied irradiating the tumor for 20min daily
for 4 days. The treatment was repeated every two weeks. After 2 or 3
cycles of SDT all the patients showed a positive partial result. These
primary clinical data showed that SDT with SF1 was well tolerated. The
authors thus concluded that SDT has a significant therapeutic effect for
patients with advanced breast cancer [183,184].
Another research group employed SDT with two new chlorophyll-
derived sono-photo-sensitizing agents developed by EEC Biotech and
approved for clinical use [185]. By previous in-vitro experiments with
human breast and lung cancer cell-lines, they showed that SDT was
strongly synergetic with chemotherapy. By means of animal studies, the
authors demonstrated that the sensitizers were specifically absorbed
into tumor cells and that SDT inhibited the growth of mouse S-180
sarcoma. They started the clinical study with seven patients who were
pathologically subjected to advanced esophagocadiac and gastric ade-
nocarcinomas. The sono-photo-dynamic therapy was concurrent with
chemotherapy within the range from moderate to half of conventional
dosages. On the light of the preliminary data, the authors suggested that
sono-photo-dynamic therapy had almost no toxicity, but might dra-
matically enhance the conventional therapeutic efficacy in advanced
refractory esophagocadiac and gastric adenocarcinomas [185].
Other clinical case studies were conducted in patients with locally
advanced and inoperable pancreatic cancers. They were treated using a
customized configuration of commercial clinical ultrasound scanners in
the presence of MBs. The combination of ultrasound, microbubbles, and
the chemotherapy in these clinical settings increased the number of
treatment cycles, prolonging the quality of life in patients with pan-
creatic adenocarcinomas compared to chemotherapy treatment alone
[147,178,186–190].
The use of hard-matter NPs (yet metal or metal oxide NPs) in clinics
assisting ultrasound can offer the advantage of having an engineered
type of nano-sensitizers acting themselves as therapeutics with ultra-
sound stimulation (US) [191]. Actually, NPs can sufficiently disperse in
aqueous solution and, thanks to their dimensions ranging from 1 to
200 nm, have more changes to avoid the activation of the complement
cascade and their eventual clearance by immune cells and macrophages
[20]. The fast nanotechnological evolution in the production of dif-
ferent kinds of NPs supports early disease diagnosis and staging, thus
enabling also image-guided therapy and personalized therapy
[192–196]. NPs application in theranostics allows to integrate diag-
nostic and therapeutic capabilities into a single nanostructure. This all-
in-one approach will enable the NPs in-vitro and in-vivo use for mon-
itoring the sites of bioaccumulation and for evaluating their therapeutic
value [197]. The design and the production of engineered hard-matter
NPs, as reported above, demonstrate a wide range of possibilities to
solve the limitation of sonosensitizer molecules and MBs-based SDT.
NPs can be able to invade tissues with an effective and localized ac-
cumulation, release the carried drugs, improving the treatment’s effi-
ciency, and minimizing the side effects [20]. By tuning the NPs design
and, more in details, their surface functionalization, it is possible to
improve active tumor targeting and avoid the hematologic toxicities. In
Harada et al. [198] the effect of US combined with the use of titanium
dioxide NP (TiO2) on C32 melanoma cells was studied in-vitro and in-
vivo. The results showed that when the tumors were treated with
TiO2 alone or only irradiated by ultrasound, the cancer progression was
unaffected as compared to control mice. Strikingly, th tumors treated by
a combination of TiO2 NPs and ultrasound irradiation resulted in a
significant inhibition of tumor growth compared with the untreated
mice. Recently, long-circulating hydrophilized TiO2NPs (HTiO2 NPs)
were designed by You et al. the authors, The authors demonstrated that,
when systemically administered to mice, HTiO2 NPs can suppress the
progression of a deep side located tumor [199]. Moosavi Nejda et al.
[200] reported that, the increased intensity of US (20, 32, 55,
73W cm−2) in in-vitro experiments using US-excited TiO2 NPs
(100 μgmL−1), improved the damage in oral squamous cell carcinoma
until reaching cells necrosis at 73W cm−2 and 3 s. Yamaguchi et al.
proposed water-dispersed TiO2 NPs and SDT as a novel cure for ma-
lignant gliomas. In particular, water-dispersed TiO2 NPs were functio-
nalized through polyethylene glycol (PEG) on their surface (TiO2/PEG)
and the survival rate of U251 human glioblastoma cells remarkably
decreased depending on the US intensity used for each treatment [191].
8. Expert opinion and future perspective
NPs are successfully assisting ultrasound applications, in particular
sonodynamic, competing with others more traditional techniques for
cancer diagnosis and treatment. At present, the wide collection of re-
sults coming out from in-vitro and in-vivo experiments confirms the
efficacy of NP-assisted ultrasound against different types of malignant
cells and tissues. However, as highlighted in the previous sections, more
studies and clinical trials will be necessary. Further researches and
sustained technological improvements are requested to develop new
and more biocompatible and effective NPs-based sensitizers. In parti-
cular, the increase the NPs-assisted STD efficacy should primarily focus
on improving the ability of NPs to induce inertial cavitation, i.e. ex-
ploiting the optimization of both the chemistry and the morphology of
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the NP surface.
Furthermore, the role of NP sonosensitizer should be further in-
vestigated and understood, especially for those particles having a
multifuncitonal and synergistic effect with the ultrasound action.
Together with the NPs properties, ultrasound irradiation can be
optimized to improve the generation of cavitating bubbles and conse-
quently the therapeutic outcome of NPs-assisted STD. Indeed, inertial
cavitation phenomenon strongly depends on ultrasonic frequency,
pressure amplitude, and, if pulsed ultrasound is used, on pulse repeti-
tion frequency and the number of cycles in each pulse [201]. In this
regard, dual frequency ultrasound irradiation has also been recently
proposed [111].
Further research toward the optimization of the ultrasound irra-
diation is expected. Moreover, it is fundamental to deeply understand
the mechanism of action of ultrasound on biological tissues. The diffi-
culty of discriminating the thermal from the mechanical effects poses
serious challenges in this regard, as well as their synergistic effect.
However, this understanding will be indispensabile to proceed toward
the clinical trials.
Concerning the SDT mechanisms, from the available data, the
contribution of sonoluminescence to the therapeutic efficacy of SDT has
still to be fully clarified. Further research is needed to definitely unravel
its role as sonosensitizer activator.
When studying and writing this review, we also noted a lack in
uniformity of the published data describing the ultrasound set up used
by different authors. In particular, data describing the power densities,
pressures, presence or absence of cavitation, and type of cavitation
obtained are all necessary to compare the different literature works
among each other.
Altogether, the optimization of both nano-sonosensitizers, with
great sonodynamic efficiency and biocompatibility, and ultrasound
protocols represents a key issue for leading SDT to successful clinical
applications.
9. Conclusions
Ultrasound-based therapies and diagnostics play a fundamental role
in the scientific research panorama and in the clinical context. Several
kinds of both soft and hard-material NPs were proposed for assisting
US-based therapies. As it clearly appears from the literature, SDT is an
innovative treatment against cancer offering a huge potential. The
cellular damage arises only when both non-toxic stimulus and sensiti-
zers are combined, thus drastically lowering side-effects compared to
traditional treatments. However, the exact physical/chemical mechan-
isms behind the observed therapeutic efficacy still need to be un-
raveled: this would open up the possibility to rationally optimize SDT
with the ultimate goal to bring this technology to the clinics.
More in general, we reported on the efficacy of NP-assisted US
against tumor cells and tissues where the working mechanism, even in
association with other therapeutic approaches in clinics, has still to be
fully understood. Therefore, further interdisciplinary scientific research
on NP-assisted US mechanisms is expected and the engagement of
biologists and physicians together with physicists, chemists and en-
gineers is highly encouraged for the future.
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